These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3301895)

  • 21. Immunological response to Clostridium botulinum toxin.
    Galazka A; Rymkiewicz D; Aleksandrowicz J
    J Clin Microbiol; 1988 Jun; 26(6):1250-1. PubMed ID: 3384942
    [No Abstract]   [Full Text] [Related]  

  • 22. In vitro assays for botulinum toxin and antitoxins.
    Shone C; Appleton N; Wilton-Smith P; Hambleton P; Modi N; Gatley S; Melling J
    Dev Biol Stand; 1986; 64():141-5. PubMed ID: 3792644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid.
    Torii Y; Tokumaru Y; Kawaguchi S; Izumi N; Maruyama S; Mukamoto M; Kozaki S; Takahashi M
    Vaccine; 2002 Jun; 20(19-20):2556-61. PubMed ID: 12057613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody for the detection of Clostridium botulinum type A toxin.
    Ferreira JL; Hamdy MK; Herd ZL; McCay SG; Zapatka FA
    Mol Cell Probes; 1987 Dec; 1(4):337-45. PubMed ID: 3453424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of type E botulinal toxin in cultures by fluorescent-antibody microscopy.
    Aalvik B; Sakaguchi G; Riemann H
    Appl Microbiol; 1973 Jan; 25(1):153-4. PubMed ID: 4568886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibody to type F Clostridium botulinum toxin.
    Ferreira JL; Hamdy MK; McCay SG; Zapatka FA
    Appl Environ Microbiol; 1990 Mar; 56(3):808-11. PubMed ID: 2180373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows.
    Krüger M; Skau M; Shehata AA; Schrödl W
    Anaerobe; 2013 Oct; 23():97-101. PubMed ID: 23831724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of Clostridium botulinum type C antitoxin titers in mink and guinea pigs to protection against type C intoxication in mink.
    Kolbe DR; Coe Clough NE
    Anaerobe; 2008 Apr; 14(2):128-30. PubMed ID: 18032073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antigenicity of Clostridium botulinum type C toxin administered per os.
    Jansen BC; Knoetze PC; Visser F
    Onderstepoort J Vet Res; 1970 Sep; 37(3):169-71. PubMed ID: 4949136
    [No Abstract]   [Full Text] [Related]  

  • 30. Humoral responses in cattle to commercial vaccines containing Clostridium perfringens epsilon toxoid and C. botulinum types C and D toxoids last less than a-year.
    Augusto de Oliveira C; Duarte MC; Antunes de Assis R; Alves GG; Silva ROS; Faria Lobato FC
    Anaerobe; 2019 Oct; 59():72-75. PubMed ID: 31129336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins.
    Torgeman A; Diamant E; Levin L; David AB; Epstein E; Girshengorn M; Mazor O; Rosenfeld R; Zichel R
    Vaccine; 2017 Dec; 35(52):7213-7216. PubMed ID: 29174678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New equine antitoxins to botulinum neurotoxins serotypes A and B.
    Li D; Mattoo P; Keller JE
    Biologicals; 2012 Jul; 40(4):240-6. PubMed ID: 22560800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinal toxin and toxoid as antigens.
    Heimach RC; Champion LA; Sugiyama H
    Proc Soc Exp Biol Med; 1970 Oct; 135(1):151-4. PubMed ID: 4920940
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan.
    Torii Y; Sugimoto N; Kohda T; Kozaki S; Morokuma K; Horikawa Y; Ginnaga A; Yamamoto A; Takahashi M
    Jpn J Infect Dis; 2017 Jul; 70(4):423-429. PubMed ID: 28250257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study on the immunological heterogeneity of Clostridium botulinum B type toxin.
    Rymkiewicz D; Sawicki J; Brühl A
    Arch Immunol Ther Exp (Warsz); 1979; 27(5):709-14. PubMed ID: 398207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1.
    Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY
    J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum toxin type A.
    Notermans S; Dufrenne J; Schothorst M
    Jpn J Med Sci Biol; 1978 Feb; 31(1):81-5. PubMed ID: 351243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological heterogeneity of Clostridium botulinum type B toxins.
    Shimizu T; Kondo H; Sakaguchi G
    Jpn J Med Sci Biol; 1974 Apr; 27(2):99-100. PubMed ID: 4134872
    [No Abstract]   [Full Text] [Related]  

  • 39. Botulinum antitoxins and antibacterial IgM and IgG antibodies in sera of persons immunized with botulinum polytoxoid combined with cholera vaccine. I. Response to botulinum toxoid.
    Galazka A; Rymkiewicz D; Aleksandrowicz J
    Arch Immunol Ther Exp (Warsz); 1976; 24(5):631-9. PubMed ID: 793566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical toxin variant of Clostridium botulinum type B associated with infant botulism.
    Hatheway CL; McCroskey LM; Lombard GL; Dowell VR
    J Clin Microbiol; 1981 Dec; 14(6):607-11. PubMed ID: 7037830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.